Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us.
Dykewicz
M S
MS
D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D015415:Biomarkers / Q000032:analysis; D001944:Breath Tests; D002986:Clinical Trials as Topic; D000068298:Fluticasone; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D009569:Nitric Oxide / Q000378:metabolism* / Q000502:physiology; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D009569:Nitric Oxide; D000068298:Fluticasone; C062735:zafirlukast